Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 1, 2012, Pages 95-100

  Lawley, Claire ^a   Wainwright, Camilla ^a,b   Segelov, Eva ^a,b   Lynch, Jodi ^c   Beith, Jane ^d   Mccrohon, Jane ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Breast cancer; Cardiac magnetic resonance imaging; Cardiotoxicity; Trastuzumab

Indexed keywords

GADOBUTROL; GADOLINIUM; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MONITORING; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART FUNCTION; HEART MUSCLE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; SYMPTOM; TISSUE INJURY; TREATMENT OUTCOME;

EID: 84857649431     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01462.x     Document Type: Article

References (32)

1. Gandy SJ, Waugh SA, Nicholas RS, Simpson HJ, Milne W, Houston JG. Comparison of the reproducibility of quantitative cardiac left ventricular assessments in healthy volunteers using different MRI scanners: a multicenter simulation. J Cardiovasc Magn Reson 2008; 28: 359-165.
2. Grothues F, Smith GC, Moon JC etal. Comparison of inter study reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002; 90: 29-34.
3. Teo KS, Carbone A, Piantadosj C etal. Cardiac MRI assessment of left and right ventricular parameters in health Australian normal volunteers. Heart Lung Circ 2008; 17: 313-7.
4. Kwong RY, Korlakunta H. Diagnostic and prognostic value of cardiac magnetic resonance imaging in assessing myocardial viability. Top Magn Reson Imaging 2008; 19: 15-24.
5. Wassmuth R, Lentzsch S, Erdbruegger U etal. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - a pilot study. Am Heart J 2001; 141: 1007-13.
6. Oberholzer K, Kunz RP, Dittrich M, Thelen M. [Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer. RoFo 2004; 176: 1245-50.
7. Olver I, Chirgwin J, Nowak A etal. Recommendations for the use of trastuzumab for the treatment of HER-2-positive breast cancer. NBCC 2007. [Cited 28 Sept 2011.] Available from .
8. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 2008; 10: 5.
9. Wadhwa D, Fallah-Rad N, Grenier D etal. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009; 117: 357-64.
10. Flett AS, Westwood MA, Davies LC, Mathur A, Moon JC. The prognostic implications of cardiovascular magnetic resonance. Circulation 2009; 2: 243-50.
11. Keefe DL. Trastuzumab-associated cardiotoxicity. [Published erratum appears in Cancer; 2003:1136.] Cancer 2002; 95: 1592-600.
12. Seidman A, Hudis C, Pierri MK etal. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21.
13. Kim RJ, Wu E, Rafael A etal. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343: 1445-53.
14. Kwong RY, Sattar H, Wu H etal. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008; 118: 1011-20.
15. Gerber BL, Garot J, Bluemke DA, Wu KC, Lima JA. Accuracy of contrast enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation 2002; 106 1083-9.
16. Adabag AS, Maron BJ, Appelbaum E etal. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51: 1369-74.
17. Moon JC, Reed E, Sheppard MN etal. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 43: 2260-4.
18. Cheong BY, Muthupillai R, Wilson JM etal. Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction. Circulation 2009; 120: 2069-76.
19. Suvarna SK. Cardiac pathology of fatal trastuzumab therapy. J Clin Pathol 2008; 61: 143-4.
20. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies.[See Comment]. Eur Heart J 2005; 26: 1461-74.
21. Hunold P, Schlosser T, Vogt FM etal. Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. Am J Roentgenol 2005; 184: 1420-6.
22. Abdel-Aty H, Boye P, Zagrosek A etal. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 2005; 45: 1815-22.
23. Breuckmann F, Mohlenkamp S, Nassenstein K etal. Myocardial late gadolinium enhancement: prevalence, pattern, and prognostic relevance in marathon runners. Radiology 2009; 251: 50-7.
24. Jerosch-Herold M, Sheridan DC, Kushner JD etal. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol 2008; 295: H1234-42.
25. Maceira AM, Joshi J, Prasad SK etal. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111: 186-93.
26. McCrohon JA, Moon JC, Prasad SK etal. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003; 108: 54-9.
27. Raman SV, Sparks EA, Baker PM, McCarthy B, Wooley CF. Mid-myocardial fibrosis by cardiac magnetic resonance in patients with lamin A/C cardiomyopathy: possible substrate for diastolic dysfunction. J Cardiovasc Magn Reson 2007; 9: 907-13.
28. Zimmermann O, Grebe O, Merkle N etal. Myocardial biopsy findings and gadolinium enhanced cardiovascular magnetic resonance in dilated cardiomyopathy. Eur J Heart Fail 2006; 8: 162-6.
29. Tan-Chiu E, Yothers G, Romond E etal. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-9.
30. Guarneri V, Lenihan D, Valero V etal. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer; The M.D. Anderson Cancer Centre Experience. J Clin Oncol 2006; 24: 4107-15.
31. Martin M, Esteva FJ, Alba E etal. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 2009; 14: 1-11.
32. Wu K, Weiss R, Thiemann D etal. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51: 2414-21.